Skip to main navigation Skip to search Skip to main content

6-month clinical outcomes following implantation of the bioresorbable everolimus-eluting vascular scaffold in vessels smaller or larger than 2.5 mm

  • Roberto Diletti
  • , Yoshinobu Onuma
  • , Vasim Farooq
  • , Josep Gomez-Lara
  • , Salvatore Brugaletta
  • , Robert Jan Van Geuns
  • , Evelyn Regar
  • , Bernard De Bruyne
  • , Dariusz Dudek
  • , Leif Thuesen
  • , Bernard Chevalier
  • , Dougal McClean
  • , Stephan Windecker
  • , Robert Whitbourn
  • , Pieter Smits
  • , Jacques Koolen
  • , Ian Meredith
  • , Dong Li
  • , Susan Veldhof
  • , Richard Rapoza
  • Hector M. Garcia-Garcia, John A. Ormiston, Patrick W. Serruys
  • Erasmus MC
  • Onze-Lieve-Vrouwziekenhuis Ziekenhuis
  • Uniwersytet Jagielloński
  • Aarhus University Hospital
  • Institut Hospitalier Jacques Cartier
  • Christchurch Hospital New Zealand
  • University Hospital of Psychiatry
  • St Vincent's Hospital
  • Maasstad Hospital
  • Catharina Hospital
  • Monash Medical Centre
  • Abbott Vascular
  • Cardialysis BV
  • Auckland City Hospital

Research output: Contribution to a Journal (Peer & Non Peer)Articlepeer-review

50 Citations (Scopus)

Abstract

Objectives: We investigated the 6-month clinical outcomes after implantation of second-generation 3.0-mm bioresorbable everolimus-eluting vascular scaffolds (BVS) in small coronary vessels (<2.5 mm). Background: BVS are a novel approach to treating coronary lesions and are untested in small vessels. Methods: The ABSORB Cohort B Trial is a multicenter, single-arm, prospective, open-label trial assessing the performance of the second-generation BVS, in which 101 patients were enrolled. The pre-procedural reference vessel diameter (RVD) was assessed by quantitative coronary angiography during post hoc analysis. The vessel size was overestimated, by visual assessment, in 41 patients before implantation of 3.0-mm BVS in vessels with a pre-procedural RVD <2.5 mm. The study population was divided into 2 groups, group I (n = 41) with RVD <2.5 mm and group II (n = 60) with RVD <2.5 mm. The composite endpoint of ischemia-driven major adverse cardiac events, defined as ischemia-driven target lesion revascularization, myocardial infarction, or cardiac death, was assessed. Of the 45 patients scheduled for 6-month coronary angiography, 42 patients had the procedure performed, with intravascular ultrasound undertaken in 40 of these patients. Results: At 6 months, no significant differences in ischemia-driven major adverse cardiac events (3 of 41 [7.3%] cases vs. 2 of 60 [3.3%] cases; p = 0.3933) were observed in the small- and large-vessel groups, respectively. No cardiac deaths or episodes of in-scaffold thromboses were seen. Angiographic and intravascular ultrasound follow-up demonstrated no differences in late lumen loss (0.16 ± 0.18 mm vs. 0.21 ± 0.17 mm; p = 0.3525) or percentage lumen area stenosis (17.6 ± 6.0% vs. 19.8 ± 8.5%; p = 0.3643). Conclusions: The second-generation 3.0-mm BVS appears to be safe in small vessels, with similar clinical and angiographic outcomes compared with those of large vessels.

Original languageEnglish
Pages (from-to)258-264
Number of pages7
JournalJournal of the American College of Cardiology
Volume58
Issue number3
DOIs
Publication statusPublished - 12 Jul 2011
Externally publishedYes

Keywords

  • bioresorbable everolimus-eluting vascular scaffold
  • outcome
  • small vessels

Fingerprint

Dive into the research topics of '6-month clinical outcomes following implantation of the bioresorbable everolimus-eluting vascular scaffold in vessels smaller or larger than 2.5 mm'. Together they form a unique fingerprint.

Cite this